Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema

Inclusion Criteria: * Male or female, who is at least 18 years of age or older at screening visit. * Presence of chronic persistent vascular facial erythema for ≥ 3 months by history. * A Clinician's Erythema Assessment (CEA) score of ≥3 at Screening and at Pre-dose (T0) on Baseline/Day 1. * A Patient Self Assessment (PSA) score of ≥3 at Screening and at Pre-dose (T0) on Baseline/Day 1. Exclusion Criteria: * More than 2 facial inflammatory lesions (papules, pustules, and nodules). * Presence of areas of significant scaling or crusting on the face. * Presence of psoriatic lesions on the face. * Presence of any other dermatological condition of the face that, in the opinion of the Investigator, may significantly interfere with the interpretation of the clinical trial results.